SOUTH SAN FRANCISCO, Calif., May 15, 2013 (GLOBE NEWSWIRE) -- Full Spectrum Genetics, Inc., a privately-held protein analysis and engineering platform and product company, today announced the successful completion of the second project for the purpose of generating multiple novel therapeutic protein and antibody product candidates.
Under the terms of the agreement, the leading global pharmaceutical company has worldwide rights to develop and commercialize product candidates arising from the collaboration. In return Full Spectrum Genetics has received multiple payments and may be eligible for more. Additional terms were not disclosed.
About Full Spectrum Genetics
Founded in 2010, Full Spectrum Genetics, Inc. is a privately-held protein analysis and engineering platform and product company. The Company's MapEng™ platform enables the ultra-high throughput quantification of the effect on binding of every possible single amino acid substitution within a protein binding site. The MapEng™ platform provides a comprehensive analysis of protein structure-function relationships, with multiple applications for generating better biotherapeutics and diagnostics. Full Spectrum Genetics' activities cover the spectrum from antibody discovery to generating proteins with improved properties including modulation of binding affinity to one or more targets, de-immunization, humanization, half-life extension and stability. For more information on Full Spectrum Genetics and its MapEng™ platform, visit www.fsgene.com.
CONTACT: Bob DuBridge CEO Full Spectrum Genetics, Inc. 650-754-7384 firstname.lastname@example.org
Source:Full Spectrum Genetics, Inc.